Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q1 2026 results and business updates. Cash was $9.3M vs. $7.6M at year-end 2025, after raising about $3.1M via its equity line. Net loss narrowed to $1.7M ($0.62/share) from $2.1M.
The company advanced ibezapolstat for C. difficile, initiating a Phase 2 rCDI trial and preparing Phase 3 acute CDI studies, while expanding its global DNA pol IIIC patent estate with new U.S. and Korean grants.
Acurx (NASDAQ: ACXP) presented preclinical data at ESCMID Global 2026 showing that its DNA pol IIIC inhibitor candidates achieved systemic antibacterial activity against MRSA in neutropenic mice while preserving gut microbiome diversity compared with linezolid. The compounds reached potentially therapeutic plasma levels and maintained a Bacteroidota-dominant community, preventing Proteobacteria expansion.
Data suggest a class effect for microbiome-sparing Gram-positive antibiotics and note FDA QIDP and Fast-Track eligibility for Acurx preclinical candidates.
Acurx Pharmaceuticals (Nasdaq: ACXP) announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on Wednesday, May 24, 2025.
A replay will be available under the News / Events tab of the Acurx website at www.acurxpharma.com following the event.
Acurx Pharmaceuticals (NASDAQ: ACXP) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 5:20 PM ET at the historic Bank of New York, 48 Wall Street, New York.
David P. Luci, President and CEO, is scheduled to give the company presentation. Attendance requires an invitation via the summit website.
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 a.m. ET before U.S. markets open. David P. Luci, president and CEO, and Robert G. Shawah, CFO, will host a conference call and provide a business update. Participant dial-in details and international toll-free numbers are available; U.S. access ID is 13760162.
Acurx Pharmaceuticals (NASDAQ: ACXP) closed a registered direct offering on April 16, 2026, selling 825,085 shares (or pre-funded warrants) at $3.03 per share for aggregate gross proceeds of approximately $2.5 million.
In a concurrent private placement the company issued immediately exercisable short-term warrants to purchase up to 1,650,170 shares at an exercise price of $2.78, exercisable for 24 months, which could raise an additional ~$4.6 million if fully exercised.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced a registered direct offering to sell 825,085 shares (or pre-funded warrants) at $3.03 per share and a concurrent private placement of short-term warrants to purchase up to 1,650,170 shares at $2.78 per warrant.
The offering is expected to close on or about April 16, 2026, providing approximately $2.5 million of upfront gross proceeds and up to $4.6 million additional proceeds if warrants are fully exercised, for total potential gross proceeds of $7.1 million.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced on March 30, 2026 that the Korean Intellectual Property Office granted a patent covering DNA Polymerase IIIC inhibitors, including compositions‑of‑matter, methods of use, and pharmaceutical formulations.
This grant adds to Acurx's expanding patent estate protecting its ACX‑375C program, following four U.S. patents and granted patents in Israel, Japan, India, Australia, and other jurisdictions. The company said its lead DNA pol IIIC inhibitor, ibezapolstat, is positioned to enter international Phase 3 pivotal registration trials in the U.S. and EU for oral acute C. difficile infection and that a trial in multiply‑recurrent CDI is starting up.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported full-year 2025 results and a business update on March 13, 2026. Key items: cash $7.6M, gross equity-line proceeds ~$4.0M in 2025, net loss $8.0M for 2025, and 2,348,113 shares outstanding.
Clinical highlights include a planned open-label 20-patient rCDI pilot, Phase 2 ibezapolstat results (96% clinical cure of 26 patients, no recurrence), a new USPTO patent to Dec 2039, and structural biology publication supporting the Pol IIIC inhibitor program.
Acurx (Nasdaq: ACXP) announced a new open-label pilot trial of ibezapolstat in multiply-recurrent C. difficile infection (rCDI) and said its broader CDI program is ready to advance to Phase 3 international trials, subject to funding.
Key details: up to 20 patients in the pilot, first patient expected to enroll in Q4 2026, prior Phase 2 results showed high clinical cure and low recurrence, and Acurx holds FDA QIDP and Fast-Track plus EMA SME designations.